Can you summarize the key features of the LEADER trial, including the primary MACE end points and the patient populations studied?
What is your assessment of the results of the secondary end points — especially renal markers such as albuminuria — reported in LEADER that may be drivers of atheroinflammatory CV disease? What about the absence of a cancer signal?
What did we learn about hypoglycemic risk from the LEADER trial as it relates to the GLP-1 RA evaluated?
Based on LEADER, what does the typical patient with T2D look like who could possibly benefit from CV risk reduction associated with GLP-1 RA therapy? What doses of liraglutide would appear to be optimal?
By what mechanisms do you think the GLP-1 RA liraglutide might have affected cardiovascular events, based on the finding of the LEADER trial?
In your mind, what are the most impressive results reported for both primary and secondary end points in the LEADER trial?
What dosing considerations should we keep in mind for liraglutide based on the results of the LEADER trial? And what are the implications for insulin-GLP-1 RA combination therapy?
How should the front-line clinician treating T2D patients translate the results of the LEADER trial into clinical practice? Have these results prioritized GLP-1 RAs in the T2D treatment pathway?
How might the results of LEADER impact the prioritization of GLP-1 RAs as foundational agents for T2D, either as stand-alone agents or in combination with SGLT2 inhibitors? Or with long-acting basal insulin?
Can you compare the results, time lines, and insights gleaned from the LEADER trial with liraglutide, a GLP-1 RA, to those reported for EMPA-REG, which evaluated the effectiveness and safety of an SGLT2 inhibitor on CV risk?
What pathophysiological and mechanistic factors associated with the GLP-1 agonist liraglutide might explain the reduction in overall mortality, MACE, and CV mortality reported in the LEADER trial?
What are we learning about the efficacy and safety of ultra-long-acting insulins such as degludec and U300 glargine?